<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04790747</url>
  </required_header>
  <id_info>
    <org_study_id>EML-001</org_study_id>
    <nct_id>NCT04790747</nct_id>
  </id_info>
  <brief_title>Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions</brief_title>
  <official_title>Clinical Trial for the Safety and Efficacy of Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yake Biotechnology Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial for the safety and efficacy of sequential radiotherapy with CAR-T cells in the&#xD;
      treatment of relapsed and refractory hematological malignancies with extramedullary lesions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single arm study. To evaluate the safety and efficacy of sequential&#xD;
      radiotherapy with CAR-T cells in the treatment of relapsed and refractory hematological&#xD;
      malignancies with extramedullary lesions. The main endpoints were dose limiting toxicity&#xD;
      (DLT) and incidence of adverse events (TEAEs).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Baseline up to 28 days after CAR-T cells infusion</time_frame>
    <description>Adverse events assessed according to NCI-CTCAE v5.0 criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 2 years after CAR-T cells infusion</time_frame>
    <description>Incidence of treatment-emergent adverse events [Safety and Tolerability]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Remission Rate</measure>
    <time_frame>up to 28 days after CAR-T cells infusion</time_frame>
    <description>Complete Remission Rate after CAR-T cell therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years after CAR-T cells infusion</time_frame>
    <description>From the first infusion of CD19 CAR-T cells to death or the last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>Up to 2 years after CAR-T cells infusion</time_frame>
    <description>From the complete remission to the occurrence of any event, including death, relapse (any one occurs first), and the last visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>At Baseline, Month 1, 3, 6, 9 and 12</time_frame>
    <description>Assessment using European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) scale [For item1-28: max score: 112, min score: 28, higher scores mean a better outcome; for item 28-29: max score: 14, min score: 2, higher scores mean a worse outcome] to measure Quality of life at Baseline, Month 1, 3, 6, 9 and 12</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>radiotherapy and CAR-T therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sequential radiotherapy and CAR-T cell therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAR-T cells</intervention_name>
    <description>Each subject receives sequential radiotherapy and CAR-T cells by intravenous infusion</description>
    <arm_group_label>radiotherapy and CAR-T therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Ageâ‰¥15 years old; Relapsed and refractory hematological malignancies with extramedullary&#xD;
        lesions, mainly including B-cell non Hodgkin's lymphoma, multiple myeloma, acute&#xD;
        lymphoblastic leukemia, etc; Flow cytometry or pathological biopsy confirmed that tumor&#xD;
        cells have potential therapeutic targets for Car-T cells; PET-CT confirmed that the&#xD;
        extramedullary lesions were located in a single radiotherapy region; Anticipated survival&#xD;
        time more than 12 weeks; Those who voluntarily participated in this trial and provided&#xD;
        informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        History of craniocerebral trauma, conscious disturbance, epilepsy, cerebrovascular&#xD;
        ischemia, and cerebrovascular hemorrhagic diseases; Electrocardiogram shows prolonged QT&#xD;
        interval, severe heart diseases such as severe arrhythmia in the past; Pregnant (or&#xD;
        lactating) women; Patients with severe active infections (excluding simple urinary tract&#xD;
        infection and bacterial pharyngitis); Active infection of hepatitis B virus or hepatitis C&#xD;
        virus; Concurrent therapy with systemic steroids within 2 weeks prior to screening, except&#xD;
        for the patients recently or currently receiving inhaled steroids; Previously treated with&#xD;
        any CAR-T cell product or other genetically-modified T cell therapies; Creatinine&gt;2.5mg/dl,&#xD;
        or ALT / AST &gt; 3 times of normal amounts, or bilirubin&gt;2.0 mg/dl; Other uncontrolled&#xD;
        diseases that were not suitable for this trial; Patients with HIV infection; Any situations&#xD;
        that the investigator believes may increase the risk of patients or interfere with the&#xD;
        results of study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>He Huang, PhD</last_name>
    <phone>86-13605714822</phone>
    <email>huanghe@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mingming Zhang, PhD</last_name>
    <phone>86-13656674208</phone>
    <email>mingmingzhang@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Hospital of Zhejiang Medical Colleage Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>He Huang, PhD</last_name>
      <phone>86-13605714822</phone>
      <email>hehuangyu@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Mingming Zhang, PhD</last_name>
      <phone>86-13656674208</phone>
      <email>mingmingzhang@zju.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 8, 2021</last_update_submitted>
  <last_update_submitted_qc>March 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>He Huang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>radiotherapy</keyword>
  <keyword>CAR-T</keyword>
  <keyword>extramedullary lesions</keyword>
  <keyword>relapsed and refractory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

